Barclays Reports $130.0 Target On Quest Diagnostics (DGX).

June 26, 2018 - By Lena Young

Quest Diagnostics Incorporated (NYSE:DGX) Corporate Logo

During 2018 Q1 the big money sentiment decreased to 0.8. That’s change of 0.12, from 2017Q4’s 0.92. 35 investors sold all, 217 reduced holdings as Quest Diagnostics Incorporated ratio is negative. 131 grew holdings while 71 funds amassed holdings. Funds hold 111.81 million shares thus 3.17% less from 2017Q4’s 115.48 million shares.

The New York-based Lazard Asset Ltd has invested 0% in Quest Diagnostics Incorporated (NYSE:DGX). Veritable Ltd Partnership reported 6,752 shs. Ghp Invest Advsr Inc reported 10,287 shs. Com Bankshares accumulated 10,618 shs. Copeland Capital Mgmt Ltd Liability Corporation invested in 1.05% or 162,535 shs. Boston Private Wealth Lc, Massachusetts-based fund reported 9,272 shs. The Kansas-based Cognios Limited Liability has invested 0.93% in Quest Diagnostics Incorporated (NYSE:DGX). Nuveen Asset Mngmt Ltd Liability Corporation reported 3,853 shs stake. 15.58M were reported by Blackrock. Jefferies Group Inc Lc has 6,610 shs. Klingenstein Fields Ltd Com has invested 0.02% of its capital in Quest Diagnostics Incorporated (NYSE:DGX). Guardian Life Of America holds 0.01% of its capital in Quest Diagnostics Incorporated (NYSE:DGX) for 313 shs. Bb&T Corporation stated it has 0.01% of its capital in Quest Diagnostics Incorporated (NYSE:DGX). Conning holds 0.03% of its capital in Quest Diagnostics Incorporated (NYSE:DGX) for 9,913 shs. Hartford Fincl Management reported 0% in Quest Diagnostics Incorporated (NYSE:DGX).

Quest Diagnostics Incorporated had 16 insider sales and 0 insider purchases since January 2, 2018. This’s net activity of $55.61 million. $189,971 worth of Quest Diagnostics Incorporated (NYSE:DGX) was sold by Doherty Catherine T. on Tuesday, February 27. LEIDEN JEFFREY M also sold $173,623 worth of Quest Diagnostics Incorporated (NYSE:DGX) on Tuesday, May 29. On Friday, March 2 4,128 shs were sold by PREVOZNIK MICHAEL E, worth $416,928. On Thursday, March 8 83,669 shs were sold by Cohen Jon R, worth $8.72 million. RUSCKOWSKI STEPHEN H sold 106,840 shs worth $11.43M. On Friday, May 25 61,533 shs were sold by GUINAN MARK, worth $6.50M.

Barclays Upgraded Quest Diagnostics (DGX)’s Stock Rating to Overweight.

The DGX’s TP after the upgrade is $130.0. Barclays has changed Quest Diagnostics (DGX)‘s rating to Overweight from Equal Weight. On Monday morning the upgrade was announced in analysts note.

DGX is touching $112.42 during the last trading session, after decreased 0.64%.Currently Quest Diagnostics Incorporated is downtrending after 2.15% change in last June 26, 2017. DGX has also 283,963 shares volume. The stock underperformed the S&P500 by 14.72%.

Quest Diagnostics Incorporated (NYSE:DGX)’s earnings report is expected on July, 24., Faxor reports. Analysts have expectation on stock’s earnings per share of $1.75. That’s up 12.90 % from last year’s $1.55 earnings per share. The profit will be $237.69M for DGX if $1.75 earnings per share becomes true. Wall Street now forecasts 15.13 % EPS growth despite Quest Diagnostics Incorporated last quarter’s EPS of $1.52.

Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally.The firm is valued at $15.27 billion. The company's Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, gene and esoteric testing, anatomic pathology, and other diagnostic information services.The P/E ratio is 20.03. This segment offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Athena Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals.

For more Quest Diagnostics Incorporated (NYSE:DGX) news announced briefly go to: Prnewswire.com, Seekingalpha.com, Benzinga.com, Benzinga.com or Benzinga.com. The titles are as follows: “AARP Invests $60M in the Dementia Discovery Fund to Kick-Start its ‘Disrupt Dementia’ Campaign” announced on June 25, 2018, “Premarket analyst action – healthcare” on June 08, 2018, “7 Biggest Price Target Changes For Monday” with a publish date: June 25, 2018, “Benzinga’s Daily Biotech Pulse: Epidiolex, Roche’s Influenza Drug Gets Priority Review Status, Xeris Jumps On …” and the last “Benzinga’s Top Upgrades, Downgrades For June 25, 2018” with publication date: June 25, 2018.

Quest Diagnostics Incorporated (NYSE:DGX) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.